The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.
Study Type
OBSERVATIONAL
Enrollment
1,494
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Goyang, South Korea
Research Site
Gwangju, South Korea
Change from baseline of the Clinical Global Impression score - Clinical Benefit Scale (CGI-CB) after 2 months of treatment with Seroquel XR
Time frame: 8 weeks
CGI-I score's change from 7th day to 8weeks
Time frame: 8 weeks
Patients' ratio who've been improved CGI-S score more than 4, from baseline to 8weeks
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Incheon, South Korea
Research Site
Jeju City, South Korea
Research Site
Kyung Gi, South Korea
Research Site
Kyungju, South Korea
Research Site
Kyungnam, South Korea
Research Site
Namyangju, South Korea
...and 1 more locations